Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$68.86 USD
+3.79 (5.82%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $69.50 +0.64 (0.93%) 6:14 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VKTX 68.86 +3.79(5.82%)
Will VKTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VKTX
Brian Big Idea On Technical Analysis
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
Other News for VKTX
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Acrivon Therapeutics, Inc. (ACRV) and Viking Therapeutics (VKTX)
Analysts Offer Insights on Healthcare Companies: Encompass Health (EHC), Universal Health (UHS) and Viking Therapeutics (VKTX)
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Acrivon Therapeutics, Inc. (ACRV) and Gain Therapeutics (GANX)
Viking Therapeutics Inc (VKTX) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update